Valuation: Exelixis, Inc.

Market Cap 13.29B 11.7B 10.79B 10.09B 18.91B 1,253B 19.26B 130B 50.23B 618B 49.89B 48.81B 2,150B P/E 2026 *
16.7x
P/E 2027 * 14.2x
Enterprise Value 12.52B 11.02B 10.17B 9.51B 17.82B 1,180B 18.15B 122B 47.32B 582B 47B 45.98B 2,025B EV / Sales 2026 *
4.82x
EV / Sales 2027 * 3.95x
Free-Float
98.18%
Yield 2026 *
-
Yield 2027 * -
1 day+2.98%
1 week+0.82%
Current month+4.73%
1 month+5.42%
3 months+27.18%
6 months+13.67%
Current year+20.63%
1 week 50.8
Extreme 50.8
53.09
1 month 48.1
Extreme 48.1036
53.93
Current year 39.71
Extreme 39.71
53.93
1 year 33.76
Extreme 33.755
53.93
3 years 18.64
Extreme 18.64
53.93
5 years 14.87
Extreme 14.87
53.93
10 years 7.43
Extreme 7.43
53.93
Manager TitleAgeSince
Chief Executive Officer 65 21/07/2010
Director of Finance/CFO 58 14/07/2015
Chief Operating Officer 63 31/01/2016
Director TitleAgeSince
Director/Board Member 70 31/01/2004
Director/Board Member 82 31/07/2004
Chairman 77 31/12/1997
Date Insider Type Main position Quantity % Market Cap.
05-31Sell

Director

-9,812 0.0039%
05-31Sell

Director

-3,925 0.0016%
05-26Free

Director

8,367 0.0033%
Change 5-day change 1-year change 3-year change Capi.($)
+2.98%+0.82%+15.64%+166.21% 12.9B
-7.92%-4.05%+53.28%+106.11% 57.55B
+8.55%+17.52%+72.65%+82.31% 47.08B
-0.45%-2.18%-14.16%-15.80% 22.92B
+1.28%+5.09%-2.30%+418.34% 22.14B
-0.80%+4.35%+25.14%-16.36% 16.33B
-0.15%+4.15%+27.79%-34.84% 15.97B
+5.94%+14.85%+134.05%+296.09% 12.85B
-0.71%+1.98%+78.88%+114.48% 11.84B
-3.60%-2.26%+23.68% - 11.84B
Average +0.49%+4.46%+41.46%+124.06% 23.14B
Weighted average by Cap. +0.04%+4.75%+43.66%+115.51%

Financials

2026 *2027 *
Net sales 2.6B 2.29B 2.11B 1.97B 3.7B 245B 3.77B 25.36B 9.82B 121B 9.76B 9.55B 420B 2.92B 2.57B 2.37B 2.22B 4.16B 276B 4.24B 28.53B 11.05B 136B 10.97B 10.74B 473B
Net income 817M 719M 663M 620M 1.16B 76.97B 1.18B 7.97B 3.09B 37.97B 3.07B 3B 132B 947M 833M 769M 719M 1.35B 89.22B 1.37B 9.24B 3.58B 44.01B 3.55B 3.48B 153B
Net Debt -770M -678M -625M -585M -1.1B -72.58B -1.12B -7.51B -2.91B -35.81B -2.89B -2.83B -125B -1.73B -1.52B -1.41B -1.31B -2.46B -163B -2.51B -16.89B -6.54B -80.48B -6.5B -6.36B -280B
Logo Exelixis, Inc.
Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.
Employees
1,077
Date Price Change Volume
24/06/26 US$52.87 +2.98% 2,931,517
23/06/26 US$51.34 -0.02% 2,574,378
22/06/26 US$51.35 -1.08% 3,504,387
18/06/26 US$51.91 -1.01% 6,545,171
17/06/26 US$52.44 +0.65% 2,016,149
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
52.87USD
Average target price
49.31USD
Spread / Average Target
-6.73%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EXEL Stock